25% Off Epitope Tag Antibodies
Rockland is actively collaborating in a venture with LIMR Development, Inc. (LDI), the business development subsidiary of the Lankenau Institute for Medical Research (LIMR). As a result, Rockland's catalog portfolio now includes exclusive LIMR monoclonal and polyclonal antibodies, which bind biomarkers crucial for cell signaling, immune system regulation, inflammatory responses, cellular metabolism, and cancer progression.
LIMR's work in cancer and inflammation is an elegant fit with Rockland's antibody portfolio and technology platform. Rockland partners with leading institutions to bring to researchers the reagents vital to the advance of their key research. The Philadelphia region is home to some of the world's finest research centers. Rockland is proud to bring the unique scientific and commercial opportunities of the LIMR/LDI/Rockland collaboration to the global research community.
LIMR Development, Inc. (LDI) is the business development subsidiary of Lankenau Institute for Medical Research (LIMR). Founded in 1927, the Lankenau Institute for Medical Research (LIMR) is an independent, non-profit biomedical research center located in suburban Philadelphia on the campus of the Lankenau Medical Center. The faculty and staff at the Institute are dedicated to advancing an understanding of the causes of cancer, heart disease and diabetes. For information about LIMR, please visit www.limr.org.
Rockland has an entire portfolio of collaborative products with LIMR and other leading institutions. Those products include:
Rockland Immunochemicals Inc.Limerick, PA 19468E-mail: email@example.comPhone: 800.656.7625